Biofrontera reports Q2 2026 results, cites pending sBCC decision and pipeline data
The company said it holds a late-September PDUFA date for Ameluz in superficial basal cell carcinoma and expects a Q1 2027 launch if approved.
SEC filing
Latest
2 stories